6 results about "Adamantane derivatives" patented technology

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

The application discloses a polyphenyl-substituted adamantane derivative monomolecular resin represented by formula IA and a preparation method and application thereof. The polyphenyl-substituted adamantane derivative monomolecular resin has good solubility in various polar solvents, is suitable for being made into a film, has a high decomposition temperature, and can well meet the requirements of a photoetching process.

The invention relates to the technical field of biomedical materials, and discloses an injectable biocompatible hydrogel based on dynamic supramolecular assembly, and the hydrogel comprises the following components by weight: 3.0-5.0% of zinc oxide nanocrystalline regenerated cellulose; 3.0%-5.0% of chondroitin sulfate; 1.5% to 2.5% of recombinant human source collagen; 1%-2% of beta-sodium glycerophosphate; 0.7%-1% of a cyclodextrin polymer; 0.4%-0.7% of an adamantane derivative; 0.3% to 0.5% of PEI-DNA nano particles; 0.1% to 0.3% of calcium citrate; 0.1% to 0.2% of sodium alginate microspheres; 0.15%-0.2% of a pH buffer agent; the preparation method comprises the following steps: taking collagen as a raw material, taking sterile deionized water and normal saline as residual components, and adjusting the components through subject-object supramolecular interaction, ionic crosslinking, collagen thermosensitive assembly and a step-by-step mixing process and structure, so that the prepared hydrogel has the advantages of dynamic reversible crosslinking, shear thinning and self-healing synergy, high biocompatibility and controllable degradation rate.

This invention belongs to the technical field of drug synthesis, specifically relating to adamantane derivatives, their synthetic methods, and applications. The adamantane derivatives described in this invention include intermediate structural formulas I, II, and III, as well as structures with the following general formula: Linker is a substituted or unsubstituted C6-C10 aryl group; R1 is hydrogen or a C1-C6 alkyl group; R2 is hydrogen, a C1-C6 alkyl group, or a nitrogen-containing or nitrogen-free structural fragment; or the overall structure of R1R2 is an N-substituted heterocyclopentyl or heterocyclohexyl group. The adamantane derivatives provided by this invention combine the adamantane structure with a portion of the OAB-14 group, altering the core structure and thus improving drug activity. This invention also provides a synthetic method for these derivatives. Through cellular activity studies, the resulting compounds are screened, demonstrating potential synergistic effects in the prevention of influenza and the treatment of Alzheimer's disease.

The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomers thereof, hydrates or solvates thereof, and a pharmaceutical composition comprising same.